Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Article English OPEN
Meyerhardt, Jeffrey A.; Ancukiewicz, Marek; Abrams, Thomas A.; Schrag, Deborah; Enzinger, Peter C.; Chan, Jennifer A.; Kulke, Matthew H.; Wolpin, Brian M.; Goldstein, Michael; Blaszkowsky, Lawrence; Zhu, Andrew X.; Elliott, Meaghan; Regan, Eileen; Jain, Rakesh K.; Duda, Dan G.;
  • Publisher: Public Library of Science (PLoS)
  • Journal: PLoS ONE,volume 7,issue 6 (issn: 1932-6203, eissn: 1932-6203)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1371/journal.pone.0038231, pmc: PMC3373492
  • Subject: Cancer Treatment | Research Article | Diagnostic Medicine | Pathology | Colon Adenocarcinoma | Biomarkers | Rectal Cancer | Antiangiogenesis Therapy | Medicine | Basic Cancer Research | Oncology | Biomarker Epidemiology | Epidemiology | Q | R | Clinical Trials (Cancer Treatment) | Metastasis | Gastrointestinal Tumors | Science | Cancers and Neoplasms | Oncology Agents | General Pathology
    mesheuropmc: neoplasms

BACKGROUND: To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer. METHODS: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinas... View more
Share - Bookmark